202 related articles for article (PubMed ID: 33267820)
1. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.
Yasuta S; Kobayashi T; Aizawa H; Takahashi S; Ikeda M; Konishi M; Kojima M; Kuno H; Uesaka K; Morinaga S; Miyamoto A; Toyama H; Takakura N; Sugimachi K; Takayama W
BMC Cancer; 2020 Dec; 20(1):1184. PubMed ID: 33267820
[TBL] [Abstract][Full Text] [Related]
2. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
3. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
4. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
5. Preoperative CT staging of borderline pancreatic cancer patients after neoadjuvant treatment: accuracy in the prediction of vascular invasion and resectability.
Ahmed SA; Mourad AF; Hassan RA; Ibrahim MAE; Soliman A; Aboeleuon E; Elbadee OMA; Hetta HF; Jabir MA
Abdom Radiol (NY); 2021 Jan; 46(1):280-289. PubMed ID: 32488556
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
[TBL] [Abstract][Full Text] [Related]
8. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05).
Takahashi S; Ohno I; Ikeda M; Kobayashi T; Akimoto T; Kojima M; Konishi M; Uesaka K
BMJ Open; 2017 Oct; 7(10):e018445. PubMed ID: 29061632
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Trial (JASPAC05).
Takahashi S; Ohno I; Ikeda M; Konishi M; Kobayashi T; Akimoto T; Kojima M; Morinaga S; Toyama H; Shimizu Y; Miyamoto A; Tomikawa M; Takakura N; Takayama W; Hirano S; Otsubo T; Nagino M; Kimura W; Sugimachi K; Uesaka K
Ann Surg; 2022 Nov; 276(5):e510-e517. PubMed ID: 33065644
[TBL] [Abstract][Full Text] [Related]
11. Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.
Einama T; Kamachi H; Tsuruga Y; Sakata T; Shibuya K; Sakamoto Y; Shimada S; Wakayama K; Orimo T; Yokoo H; Kamiyama T; Katoh N; Uchinami Y; Mitsuhashi T; Taketomi A
Medicine (Baltimore); 2018 Aug; 97(31):e11309. PubMed ID: 30075497
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer.
Yabushita Y; Matsuyama R; Miyake K; Homma Y; Kumamoto T; Misumi T; Hata M; Yamanaka S; Fujii S; Endo I
J Hepatobiliary Pancreat Sci; 2023 Apr; 30(4):493-502. PubMed ID: 36178433
[TBL] [Abstract][Full Text] [Related]
14. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
[TBL] [Abstract][Full Text] [Related]
16. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution.
Masui T; Nagai K; Anazawa T; Sato A; Uchida Y; Nakano K; Yogo A; Kaneda A; Nakamura N; Yoshimura M; Mizowaki T; Uza N; Fukuda A; Matsumoto S; Kanai M; Isoda H; Mizumoto M; Seo S; Hata K; Taura K; Kawaguchi Y; Takaori K; Uemoto S; Hatano E
BMC Cancer; 2022 Jan; 22(1):119. PubMed ID: 35093003
[TBL] [Abstract][Full Text] [Related]
17. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).
Okada KI; Kawai M; Hirono S; Kojima F; Tanioka K; Terada M; Miyazawa M; Kitahata Y; Iwahashi Y; Ueno M; Hayami S; Murata SI; Shimokawa T; Yamaue H
Langenbecks Arch Surg; 2020 Feb; 405(1):23-33. PubMed ID: 31993737
[TBL] [Abstract][Full Text] [Related]
20. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Nishiwada S; Tamamoto T; Nishiofuku H; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
Langenbecks Arch Surg; 2015 May; 400(4):477-85. PubMed ID: 25929828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
